Join us at the ADC Linker & Conjugation Summit 2025 in Boston MA.

Join us at our booth to discuss the crucial role of linker payload architecture in the successful design of your drug candidate. ADC Linker & Conjugation Summit, August 19-21, 2025, in Boston, MA.

Connect with our experts Dr Francisco Velázquez, Senior Director of Chemistry, and Dr Rebecca Goydel, Senior Director of Business Development, who have a wide range of expertise in mAbs, linkers, and payloads can help you create a robust lead drug candidate. Discover how we can assist you in developing a safe and effective ADC drug by seamlessly integrating the desired linker, payload, and monoclonal antibody (mAb).

Don’t miss the talk on Accelerating ADC Development and Manufacturing with ThioBridge™ Conjugation and Linker Technology with Francisco Velázquez.

This presentation will highlight ThioBridge^TM as an efficient site-specific conjugation technology to generate antibody-drug conjugates and other conjugate modalities such as oligoconjugates and conjugates for diagnostic applications.  Attendees will gain insight into:

• ThioBridge^TM conjugation technology insights.  How the technology works and its advantages over stochastic conjugation technologies.
• Modulation of Drug-Antibody Ratio (DAR) using ThioBridge as an effective feature to optimize therapeutic activity.
• In vitro and in vivo stability of ADCs generated using ThioBridge^TM
• Optimization of linker architecture to enhance in vivo efficacy of ThioBridge^TM ADCs.  In vivo data for relevant ADCs generated using ThioBridge^TM technology
• ThioBridge^TM linker-payload and ADC manufacturing considerations.